719 related articles for article (PubMed ID: 15342913)
21. Characterization of the human immune response to the UK anthrax vaccine.
Baillie L; Townend T; Walker N; Eriksson U; Williamson D
FEMS Immunol Med Microbiol; 2004 Oct; 42(2):267-70. PubMed ID: 15364114
[TBL] [Abstract][Full Text] [Related]
22. DNA vaccination against anthrax in mice-combination of anti-spore and anti-toxin components.
Hahn UK; Boehm R; Beyer W
Vaccine; 2006 May; 24(21):4569-71. PubMed ID: 16157424
[TBL] [Abstract][Full Text] [Related]
23. Neutralizing activity of vaccine-induced antibodies to two Bacillus anthracis toxin components, lethal factor and edema factor.
Taft SC; Weiss AA
Clin Vaccine Immunol; 2008 Jan; 15(1):71-5. PubMed ID: 18032590
[TBL] [Abstract][Full Text] [Related]
24. In vitro correlate of immunity in a rabbit model of inhalational anthrax.
Pitt ML; Little SF; Ivins BE; Fellows P; Barth J; Hewetson J; Gibbs P; Dertzbaugh M; Friedlander AM
Vaccine; 2001 Sep; 19(32):4768-73. PubMed ID: 11535328
[TBL] [Abstract][Full Text] [Related]
25. Recombinant vaccine displaying the loop-neutralizing determinant from protective antigen completely protects rabbits from experimental inhalation anthrax.
Oscherwitz J; Yu F; Jacobs JL; Cease KB
Clin Vaccine Immunol; 2013 Mar; 20(3):341-9. PubMed ID: 23283638
[TBL] [Abstract][Full Text] [Related]
26. A Bivalent Protein r-PAbxpB Comprising PA Domain IV and Exosporium Protein BxpB Confers Protection Against
Majumder S; Das S; Somani VK; Makam SS; Kingston JJ; Bhatnagar R
Front Immunol; 2019; 10():498. PubMed ID: 30941133
[TBL] [Abstract][Full Text] [Related]
27. The detection of protective antigen (PA) associated with spores of Bacillus anthracis and the effects of anti-PA antibodies on spore germination and macrophage interactions.
Cote CK; Rossi CA; Kang AS; Morrow PR; Lee JS; Welkos SL
Microb Pathog; 2005; 38(5-6):209-25. PubMed ID: 15925272
[TBL] [Abstract][Full Text] [Related]
28. Potentiation of anthrax vaccines using protective antigen-expressing viral replicon vectors.
Wang HC; An HJ; Yu YZ; Xu Q
Immunol Lett; 2015 Feb; 163(2):206-13. PubMed ID: 25102364
[TBL] [Abstract][Full Text] [Related]
29. Enhancement of antibody responses to Bacillus anthracis protective antigen domain IV by use of calreticulin as a chimeric molecular adjuvant.
Park YS; Lee JH; Hung CF; Wu TC; Kim TW
Infect Immun; 2008 May; 76(5):1952-9. PubMed ID: 18285494
[TBL] [Abstract][Full Text] [Related]
30. Protection of mice against challenge with Bacillus anthracis STI spores after DNA vaccination.
Hahn UK; Alex M; Czerny CP; Böhm R; Beyer W
Int J Med Microbiol; 2004 Jul; 294(1):35-44. PubMed ID: 15293452
[TBL] [Abstract][Full Text] [Related]
31. Sequential B-cell epitopes of Bacillus anthracis lethal factor bind lethal toxin-neutralizing antibodies.
Nguyen ML; Crowe SR; Kurella S; Teryzan S; Cao B; Ballard JD; James JA; Farris AD
Infect Immun; 2009 Jan; 77(1):162-9. PubMed ID: 18981257
[TBL] [Abstract][Full Text] [Related]
32. Intranasal administration of dry powder anthrax vaccine provides protection against lethal aerosol spore challenge.
Huang J; Mikszta JA; Ferriter MS; Jiang G; Harvey NG; Dyas B; Roy CJ; Ulrich RG; Sullivan VJ
Hum Vaccin; 2007; 3(3):90-3. PubMed ID: 17375001
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of recombinant anthrax vaccine against Bacillus anthracis aerosol spore challenge: preclinical evaluation in rabbits and Rhesus monkeys.
Chawla A; Midha S; Bhatnagar R
Biotechnol J; 2009 Mar; 4(3):391-9. PubMed ID: 19296443
[TBL] [Abstract][Full Text] [Related]
34. Efficacious, nontoxigenic Bacillus anthracis spore vaccines based on strains expressing mutant variants of lethal toxin components.
Mendelson I; Gat O; Aloni-Grinstein R; Altboum Z; Inbar I; Kronman C; Bar-Haim E; Cohen S; Velan B; Shafferman A
Vaccine; 2005 Dec; 23(48-49):5688-97. PubMed ID: 16039760
[TBL] [Abstract][Full Text] [Related]
35. Genetic immunization against anthrax.
Galloway D; Liner A; Legutki J; Mateczun A; Barnewall R; Estep J
Vaccine; 2004 Apr; 22(13-14):1604-8. PubMed ID: 15068841
[TBL] [Abstract][Full Text] [Related]
36. Anthrax Vaccine Precipitated Induces Edema Toxin-Neutralizing, Edema Factor-Specific Antibodies in Human Recipients.
Dumas EK; Gross T; Larabee J; Pate L; Cuthbertson H; Charlton S; Hallis B; Engler RJM; Collins LC; Spooner CE; Chen H; Ballard J; James JA; Farris AD
Clin Vaccine Immunol; 2017 Nov; 24(11):. PubMed ID: 28877928
[TBL] [Abstract][Full Text] [Related]
37. Protection of farm goats by combinations of recombinant peptides and formalin inactivated spores from a lethal Bacillus anthracis challenge under field conditions.
Koehler SM; Buyuk F; Celebi O; Demiraslan H; Doganay M; Sahin M; Moehring J; Ndumnego OC; Otlu S; van Heerden H; Beyer W
BMC Vet Res; 2017 Jul; 13(1):220. PubMed ID: 28701192
[TBL] [Abstract][Full Text] [Related]
38. Progress and novel strategies in vaccine development and treatment of anthrax.
Chitlaru T; Altboum Z; Reuveny S; Shafferman A
Immunol Rev; 2011 Jan; 239(1):221-36. PubMed ID: 21198675
[TBL] [Abstract][Full Text] [Related]
39. BclA and toxin antigens augment each other to protect NMRI mice from lethal Bacillus anthracis challenge.
Köhler SM; Baillie LW; Beyer W
Vaccine; 2015 Jun; 33(24):2771-7. PubMed ID: 25917676
[TBL] [Abstract][Full Text] [Related]
40. A synthetic peptide vaccine directed against the 2ß2-2ß3 loop of domain 2 of protective antigen protects rabbits from inhalation anthrax.
Oscherwitz J; Yu F; Cease KB
J Immunol; 2010 Sep; 185(6):3661-8. PubMed ID: 20696862
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
